PURPOSE: Quality of life (QoL) is frequently impaired in patients suffering from malignant disease. Disturbed metabolism of neurotransmitter serotonin might be crucially involved, and serotonin-precursor tryptophan is degraded during pro-inflammatory immune response. In this study, we compared QoL and fatigue self-rating scores of patients with various types of malignancy with tryptophan metabolic changes and immune activation status. METHODS: Venous blood was collected from 146 patients with gastrointestinal tumors (n = 43), hematological malignancy (n = 40), gynecological neoplasms (n = 26), lung cancer (n = 20) and from tumors of other localization (n = 17). RESULTS: QoL was significantly reduced in patients suffering from progressive tumor disease in comparison to stable or remitting disease, also feeling of fatigue was increased (both P < 0.001). Serum tryptophan concentrations were lower in patients with progressive disease (P < 0.01), and decreased tryptophan concentrations were related to decreased QoL (r(s) = 0.256, P < 0.01) and increased fatigue (r(s) = -0.179; P < 0.05). Concentrations of tryptophan and kynurenine and the kynurenine to tryptophan ratio were predictive for impaired QoL and increased fatigue in univariate regression analysis, in multivariate analysis higher ESR and neopterin concentration in combination with stage of disease predicted QoL deterioration. CONCLUSIONS: Results suggest that immune-mediated tryptophan degradation may contribute to cancer-induced QoL deterioration.
PURPOSE: Quality of life (QoL) is frequently impaired in patients suffering from malignant disease. Disturbed metabolism of neurotransmitter serotonin might be crucially involved, and serotonin-precursor tryptophan is degraded during pro-inflammatory immune response. In this study, we compared QoL and fatigue self-rating scores of patients with various types of malignancy with tryptophan metabolic changes and immune activation status. METHODS: Venous blood was collected from 146 patients with gastrointestinal tumors (n = 43), hematological malignancy (n = 40), gynecological neoplasms (n = 26), lung cancer (n = 20) and from tumors of other localization (n = 17). RESULTS: QoL was significantly reduced in patients suffering from progressive tumor disease in comparison to stable or remitting disease, also feeling of fatigue was increased (both P < 0.001). Serum tryptophan concentrations were lower in patients with progressive disease (P < 0.01), and decreased tryptophan concentrations were related to decreased QoL (r(s) = 0.256, P < 0.01) and increased fatigue (r(s) = -0.179; P < 0.05). Concentrations of tryptophan and kynurenine and the kynurenine to tryptophan ratio were predictive for impaired QoL and increased fatigue in univariate regression analysis, in multivariate analysis higher ESR and neopterin concentration in combination with stage of disease predicted QoL deterioration. CONCLUSIONS: Results suggest that immune-mediated tryptophan degradation may contribute to cancer-induced QoL deterioration.
Authors: Dean G Cruess; John M Petitto; Jane Leserman; Steven D Douglas; David R Gettes; Thomas R Ten Have; Dwight L Evans Journal: CNS Spectr Date: 2003-01 Impact factor: 3.790
Authors: Catherine Uyttenhove; Luc Pilotte; Ivan Théate; Vincent Stroobant; Didier Colau; Nicolas Parmentier; Thierry Boon; Benoît J Van den Eynde Journal: Nat Med Date: 2003-09-21 Impact factor: 53.440
Authors: Mirjam A G Sprangers; Melissa S Y Thong; Meike Bartels; Andrea Barsevick; Juan Ordoñana; Qiuling Shi; Xin Shelley Wang; Pål Klepstad; Eddy A Wierenga; Jasvinder A Singh; Jeff A Sloan Journal: Qual Life Res Date: 2014-03-07 Impact factor: 4.147
Authors: Raf Brouns; Robert Verkerk; Tony Aerts; Didier De Surgeloose; Annick Wauters; Simon Scharpé; Peter P De Deyn Journal: Neurochem Res Date: 2010-05-19 Impact factor: 3.996
Authors: Hongjin Li; Tingting Liu; Lacey W Heinsberg; Mark B Lockwood; Derek A Wainwright; Min Kyeong Jang; Ardith Z Doorenbos Journal: Biol Res Nurs Date: 2020-06-30 Impact factor: 2.522
Authors: Christiane A Opitz; Ulrike M Litzenburger; Uta Opitz; Felix Sahm; Katharina Ochs; Christian Lutz; Wolfgang Wick; Michael Platten Journal: PLoS One Date: 2011-05-20 Impact factor: 3.240
Authors: A K Smith; J S Simon; E L Gustafson; S Noviello; J F Cubells; M P Epstein; D J Devlin; P Qiu; J K Albrecht; C A Brass; M S Sulkowski; J G McHutchinson; A H Miller Journal: Mol Psychiatry Date: 2011-06-21 Impact factor: 15.992
Authors: C L Raison; R Dantzer; K W Kelley; M A Lawson; B J Woolwine; G Vogt; J R Spivey; K Saito; A H Miller Journal: Mol Psychiatry Date: 2009-11-17 Impact factor: 15.992